Estrogen acts on target cells through estrogen receptor 1 (ESR1) or 2 (ESR2) (Kuiper et al., 1996) and genetic mutations in both ESR1 and 2 are associated with the risk of AIS development (Wang et al., 2020a). Here, ESR2 is linked to androgen insensitivity syndrome.